Stalevo/Comtan (Parkinsons Disease) Market Size, Share and Forecast Report 2022: Radiant Insights, Inc

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly.

Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Browse Full Report With TOC @ http://www.radiantinsights.com/research/stalevo-comtan-parkinson-s-disease-forecast-and-market-analysis-to-2022

Comtan (entacapone) was developed by Orion for Parkinson’s disease patients who experience end-of-dose wearing-off. The product, known as Comtan, is co-marketed with Novartis across the US, certain European markets, Brazil, and Japan. Orion has exclusive rights to the Nordic and Baltic countries, where the company is based, the UK, Ireland, and Germany, and is known as Comtess in these markets.

Comtan/Comtess was first approved and launched in Europe in 1998, and launched a year later in the US. Additionally, entacapone is one of the active ingredients in Stalevo, a triple-combination pill with carbidopa, levodopa, and entacapone, co-marketed with Novartis.

Scope

– Overview of Parkinson’s disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

– Detailed information on Stalevo including product description, safety and efficacy profiles as well as a SWOT analysis.

– Sales forecast for Stalevo for the top eight countries from 2012 to 2022.

– Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Brazil.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return

– Stay ahead of the competition by understanding the changing competitive landscape for Parkinson’s disease

– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

– Make more informed business decisions from insightful and in-depth analysis of Stalevo performance

– Obtain sales forecast for Stalevo from 2012-2022 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Brazil).

About Us

 

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s